Research On Data Management Of Innovative Drug Supply In China

As a kind of commodity,the supply of innovative drugs is divided into four stages: production,exchange,circulation and consumption.At present,the core problem of the supply of innovative drugs in China is the lack of supply.There are many problems that affect the lack of supply.The low level of productivity is the decisive factor,which is reflected in the low efficiency of research and development of innovative drugs and the low output.For the highly data-based innovative pharmaceutical industry,data management is the foundation of the industry.Based on the analysis of the current situation of innovative drugs,this paper finds that the current situation of data management in China seriously restricts the improvement of R & D efficiency and the investment of social means of production.According to the current situation of the development of biomedicine,the logic of innovative drugs’ research and development is based on basic theoretical research,through the way of hypothesis and test,through different models for evaluation,and widely use statistics and mathematics to process data.The two most important indicators of innovative drugs are the effectiveness and safety of drugs,which are verified by collecting and analyzing all kinds of data generated in specific experimental research.As an important node for regulators to judge whether innovative drugs are allowed to enter the production and circulation links,the regulatory department also judges the data and information provided by innovative drugs’ research and development institutions,and if they meet the criteria for listing,they can obtain the listing approval.Through literature analysis,this paper sorts out the current data situation in China,and finds that the data problem is very serious,this is not a case,but a problem of the whole industry.This paper explores the causes of data management problems,and finds that the data involved in innovative drugs are easy to be tampered with or falsified.Data fraud can bring huge economic benefits compared with the characteristics of innovative drugs’ industry: high investment,long cycle and low success rate.Because it is very difficult to supervise the data of innovative drugs’ listing and declaration,and it is difficult to judge the authenticity of the data,there is no very good data supervision method in the world at present.The United States,which is recognized by the world as having a high level of regulation,is often exposed to data scandals.The conclusion of this paper is: to improve the supply of innovative drugs in China,we must improve the research and development ability of innovative drugs.To improve the research and development ability of innovative drugs,we have to solve the problem of innovative drug data management first.So the logic of this paper is to improve the authenticity of data through the application of science and technology.With the development of technology,such as artificial intelligence,Internet plus and blockchain,the technology is more and more mature,which can effectively solve the confusion in current data management.Promote the socialization of data supervision through open and transparent programs.At the end of the paper,through the reflection of innovative medicine data,the advantages and disadvantages of data are analyzed,and the development direction of innovative drugs’ industry is philosophically reflected.